EXICURE INC (XCUR) Stock Price & Overview
NASDAQ:XCUR • US30205M3097
Current stock price
The current stock price of XCUR is 4.2 USD. Today XCUR is up by 6.6%. In the past month the price decreased by -1.64%. In the past year, price decreased by -67.26%.
XCUR Key Statistics
- Market Cap
- 26.754M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.07
- Dividend Yield
- N/A
XCUR Stock Performance
XCUR Stock Chart
XCUR Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to XCUR. When comparing the yearly performance of all stocks, XCUR is a bad performer in the overall market: 94.59% of all stocks are doing better.
XCUR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XCUR. XCUR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XCUR Earnings
XCUR Forecast & Estimates
XCUR Groups
Sector & Classification
XCUR Financial Highlights
Over the last trailing twelve months XCUR reported a non-GAAP Earnings per Share(EPS) of -3.07. The EPS decreased by -35.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.45% | ||
| ROE | -133.23% | ||
| Debt/Equity | 0 |
XCUR Ownership
XCUR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XCUR
Company Profile
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
Company Info
IPO: 2018-05-09
EXICURE INC
2430 N. Halsted St.
Chicago ILLINOIS 60614 US
CEO: David A. Giljohann
Employees: 7
Phone: 18476731707
EXICURE INC / XCUR FAQ
Can you describe the business of EXICURE INC?
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
What is the stock price of EXICURE INC today?
The current stock price of XCUR is 4.2 USD. The price increased by 6.6% in the last trading session.
Does EXICURE INC pay dividends?
XCUR does not pay a dividend.
What is the ChartMill technical and fundamental rating of XCUR stock?
XCUR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for XCUR stock?
EXICURE INC (XCUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.07).
Can you provide the market cap for EXICURE INC?
EXICURE INC (XCUR) has a market capitalization of 26.75M USD. This makes XCUR a Nano Cap stock.
Can you provide the ownership details for XCUR stock?
You can find the ownership structure of EXICURE INC (XCUR) on the Ownership tab.